**Core Concept**
Hepatitis C virus (HCV) infection in children is a significant concern due to its potential for chronicity and liver damage. The treatment of choice in children with HCV infection is a topic of ongoing research and has evolved over time.

**Why the Correct Answer is Right**
The treatment of choice for HCV infection in children is a combination of direct-acting antivirals (DAAs). DAAs work by targeting specific proteins involved in the HCV life cycle, such as the NS3/4A protease and the NS5A protein. This approach has shown high cure rates and a favorable safety profile in children. The use of DAAs has revolutionized the treatment of HCV infection, allowing for shorter treatment durations and higher efficacy rates compared to traditional interferon-based therapies.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because pegylated interferon and ribavirin, a traditional treatment for HCV, have been largely replaced by DAAs due to their lower efficacy and higher side effect profile in children.
**Option B:** This option is incorrect because telaprevir, an NS3/4A protease inhibitor, was withdrawn from the market due to concerns about its safety and efficacy.
**Option C:** This option is incorrect because boceprevir, another NS3/4A protease inhibitor, is no longer recommended as a first-line treatment for HCV due to its lower efficacy and higher side effect profile compared to DAAs.

**Clinical Pearl / High-Yield Fact**
It is essential for healthcare providers to stay up-to-date with the latest treatment guidelines for HCV infection in children, as the landscape of available therapies continues to evolve.

**Correct Answer: C. Sofosbuvir and ledipasvir combination.**